Literature DB >> 1596698

Susceptibility of normal and arthritic human articular cartilage to degradative stimuli.

S Ismaiel1, R M Atkins, M F Pearse, P A Dieppe, C J Elson.   

Abstract

Recombinant interleukin-1 (IL-1) alpha and beta stimulated significant loss of glycosaminoglcan (GAG) content from normal (non-arthritic) articular cartilage explants but only after incubation for 14 days and only in specimens from 8/21 (38%) individuals. By contrast, all cartilage specimens but one from patients with osteoarthritis (OA) and rheumatoid arthritis (RA) were degraded (as judged by their reduced GAG content) by the recombinant cytokines but again only after 14 days' incubation. The reduction in GAG induced by IL-1 was also greater for both OA and RA cartilage than normal cartilage. Synovial fluids (SFs) from RA patients stimulated greater loss of GAG content from OA cartilage explants than normal explants although in both cases the loss was evident within 2 days. It is concluded that cartilage explants from some individuals are susceptible to the degradative effects of IL-1 whereas others are refractory and that arthritic cartilage is more susceptible to degradation by both IL-1 and RA SFs than non-arthritic cartilage.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596698     DOI: 10.1093/rheumatology/31.6.369

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  9 in total

1.  Beneficial effects of cerium oxide nanoparticles in development of chondrocyte-seeded hydrogel constructs and cellular response to interleukin insults.

Authors:  Sathish Ponnurangam; Grace D O'Connell; Irina V Chernyshova; Katherine Wood; Clark Tung-Hui Hung; Ponisseril Somasundaran
Journal:  Tissue Eng Part A       Date:  2014-06-25       Impact factor: 3.845

2.  Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis.

Authors:  J B van Meurs; P L van Lent; A A van de Loo; A E Holthuysen; E K Bayne; I I Singer; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1999-06       Impact factor: 19.103

3.  Detection of tumour necrosis factor alpha and interleukin-1 beta in the rheumatoid osteoarthritic cartilage-pannus junction by immunohistochemical methods.

Authors:  V E Miller; K Rogers; K D Muirden
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

4.  Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants.

Authors:  A L Stevens; C A Wheeler; S R Tannenbaum; A J Grodzinsky
Journal:  Osteoarthritis Cartilage       Date:  2007-10-10       Impact factor: 6.576

5.  Independent effects of interleukin 1 on proteoglycan synthesis and proteoglycan breakdown of bovine articular cartilage in vitro.

Authors:  J Neidel; U Zeidler
Journal:  Agents Actions       Date:  1993-05

6.  Inhibition of interleukin 1 beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391.

Authors:  M P Seed; S Ismaiel; C Y Cheung; T A Thomson; C R Gardner; R M Atkins; C J Elson
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

7.  Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory.

Authors:  Jenn-Haung Lai; Shue-Fen Luo; Li-Feng Hung; Chuan-Yueh Huang; Shiu-Bii Lien; Leou-Chyr Lin; Feng-Cheng Liu; B Linju Yen; Ling-Jun Ho
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

8.  Absolute quantification of selected proteins in the human osteoarthritic secretome.

Authors:  Mandy J Peffers; Robert J Beynon; Peter D Clegg
Journal:  Int J Mol Sci       Date:  2013-10-15       Impact factor: 5.923

9.  Ginkgo biloba extract individually inhibits JNK activation and induces c-Jun degradation in human chondrocytes: potential therapeutics for osteoarthritis.

Authors:  Ling-Jun Ho; Li-Feng Hung; Feng-Cheng Liu; Tsung-Yun Hou; Leou-Chyr Lin; Chuan-Yueh Huang; Jenn-Haung Lai
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.